Condition: HR Positive/HER2 Low Breast Cancer · Sponsor: First Affiliated Hospital of Zhejiang University
This study is a prospective, multi-cohort, multicenter, open-label exploratory clinical trial. The primary study objective is to evaluate the pathologic complete response (PCR) of treatment of HR+/HER2-low breast cancer with neoadjuvant therapy combined with Trastuzumab Rezetecan and Toripalimab , including the incidences and types of adverse events. The secondary endpoints include event-free survival (EFS), residual cancer burden (RCB), and objective response rate (ORR).
This description comes directly from the study's public registry record.
Zhijun Dai · +86 157 0581 9132 · dzj0911@126.com
Wanting Shao · +86 13777556621 · shaowt111@163.com
Always discuss trial participation with your own doctor first.
| Harbin Medical University Cancer Hospital | Harbin, China | Recruiting |
| The First Affiliated Hospital of Anhui Medical University | Hefei, China | Recruiting |
| Zhongshan Hospital, Fudan University | Shanghai, China | Recruiting |
| The Second Affiliated Hospital of Xi'an Jiaotong University | Xi'an, China | Recruiting |
| The Second Affiliated Hospital of Xi'an Jiaotong University | Zhengzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07383818